ImmuneRegen BioSciences, Inc. and DelSite Biotechnologies, Inc. Collaborate on New Flu Treatment

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen® BioSciences, Inc., a wholly owned biotechnology product development and licensing subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), announced today it has commenced a collaboration with DelSite Biotechnologies, Inc., a wholly owned subsidiary of Carrington Laboratories (CARN.OB), to develop a new vaccine adjuvant system that provides both immediate and sustained immunostimulation for more effective protection against a variety of transmittable pathogens.